drugset / Trial / NCT00212381

Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

NCT00212381 ↗

Phase 3 Completed 62 enrolled New York Presbyterian Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical dysplasia in otherwise healthy women.

Timeline

Start
2000-09
Primary completion
2006-01
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ARUNDINE Small molecule 2 mg/kg Oral

Indications